Ersin Sapmaz1, Hasan Çaylak1, Kuthan Kavaklı1, Mehmet Gamsızkan2, Yusuf Sinan Şirin3, Onur Genç1. 1. Department of Thoracic Surgery, University of Health Sciences, Gülhane Training and Research Hospital, Ankara, Turkey. 2. Department of Pathology, Medicine Faculty of Düzce University, Düzce, Turkey. 3. Department of Surgery Mehmet Akif Ersoy University Veterinary Faculty Animal Hospital, Burdur, Turkey.
Abstract
BACKGROUND: This study aims to investigate the preventive effect of proanthocyanidin against ischemia-reperfusion injury after lung transplantation. METHODS: The study included 12 swines (weighing 35±5 kg) and separated into four groups. Groups 1 and 3 were identified as control groups and left upper lobectomy was performed. Groups 2 and 4 were identified as transplantation groups and left lower lobectomy and heterotransplantation were performed. Proanthocyanidin was only given to groups 3 and 4. Tissue samples were analyzed under light microscope and histopathological findings were recorded. RESULTS: There was no statistically significant difference between control groups in terms of the numerical values of histopathological findings that include congestion (p=0.565), alveolar edema (p=0.197) and peribronchial inflammation (p=0.444). However, numerical values of acute cellular rejection were statistically significantly different between transplantation groups (p=0.048). Mean oxidative stress enzyme levels were higher in group 2 compared to group 4; however, the difference was not statistically significant (p>0.05). CONCLUSION: According to the findings of our experimental study, proanthocyanidin can be safely used in lung transplantation based on its preventive effect in ischemia-reperfusion injury that may lead to morbidity and mortality.
BACKGROUND: This study aims to investigate the preventive effect of proanthocyanidin against ischemia-reperfusion injury after lung transplantation. METHODS: The study included 12 swines (weighing 35±5 kg) and separated into four groups. Groups 1 and 3 were identified as control groups and left upper lobectomy was performed. Groups 2 and 4 were identified as transplantation groups and left lower lobectomy and heterotransplantation were performed. Proanthocyanidin was only given to groups 3 and 4. Tissue samples were analyzed under light microscope and histopathological findings were recorded. RESULTS: There was no statistically significant difference between control groups in terms of the numerical values of histopathological findings that include congestion (p=0.565), alveolar edema (p=0.197) and peribronchial inflammation (p=0.444). However, numerical values of acute cellular rejection were statistically significantly different between transplantation groups (p=0.048). Mean oxidative stress enzyme levels were higher in group 2 compared to group 4; however, the difference was not statistically significant (p>0.05). CONCLUSION: According to the findings of our experimental study, proanthocyanidin can be safely used in lung transplantation based on its preventive effect in ischemia-reperfusion injury that may lead to morbidity and mortality.
Authors: Sebastian-P Sommer; Bernhard Gohrbandt; Stefan Fischer; Jens M Hohlfeld; Gregor Warnecke; Murat Avsar; Martin Strüber Journal: J Thorac Cardiovasc Surg Date: 2005-09 Impact factor: 5.209
Authors: Zequan Yang; Ashish K Sharma; Joel Linden; Irving L Kron; Victor E Laubach Journal: J Thorac Cardiovasc Surg Date: 2009-03 Impact factor: 5.209